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Abstract: Inﬂ  ammation encompasses diverse molecular pathways, and it is intertwined with 
a wide array of biological processes. Recently, there has been an upsurge of interest in the 
interactions between mediators of inﬂ  ammation and other cells such as stem cells and cancer 
cells. Since tissue injuries are associated with the release of inﬂ  ammatory mediators, it would 
be difﬁ  cult to address this subject without considering the implications of their systemic effects. 
In this review, we discuss the effects of inﬂ  ammatory reactions on stem cells and extrapolate 
on information pertaining to cancer biology. The discussion focuses on integrins and cyto-
kines, and identiﬁ  es the transcription factor, nuclear factor-kappa B (NFκB) as central to the 
inﬂ  ammatory response. Since stem cell therapy has been proposed for type II diabetes mellitus, 
metabolic syndrome, pulmonary edema, these disorders are used as examples to discuss the 
roles of inﬂ  ammatory mediators. We propose prospects for future research on targeting the 
NFκB signaling pathway. Finally, we explore the bridge between inﬂ  ammation and stem cells, 
including neural stem cells and adult stem cells from the bone marrow. The implications of 
mesenchymal stem cells in regenerative medicine as pertaining to inﬂ  ammation are vast based 
on their anti-inﬂ  ammatory and immunosuppressive effects. Such features of stem cells offer 
great potential for therapy in graft-versus-host disease, conditions with a signiﬁ  cant inﬂ  amma-
tory component, and tissue regeneration.
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Inﬂ  ammation in tumorigenesis
As early as the 1800s, scientists have proposed a relationship between cancer and 
chronic inﬂ  ammation.1,2 This connection is based on the observation of uncontrolled 
cell proliferation at sites of inﬂ  ammation and the observation of inﬂ  ammatory cells 
at regions of the cancer.1 Currently, there is resurgence of interests in the relationship 
between inﬂ  ammation and cancer. Epidemiological studies conﬁ  rmed that chronic 
inﬂ  ammation renders individuals more susceptible to cancer.3 Studies now suggest 
that nearly one of ﬁ  ve cancer deaths is due to malignancies triggered by chronic 
inﬂ  ammation.1 Additionally, chronic inﬂ  ammation has been linked to the prolifera-
tion and metastasis of tumors.3 Therefore, it could be surmised that suppression of 
chronic inﬂ  ammation could lead to a decrease in tumorigenesis, hence a decrease in 
cancer-related fatality.
The etiology of cancer is complex, although inﬂ  ammation appears to be a recur-
ring theme when this topic is discussed. For example, carcinogens in foods can 
trigger inﬂ  ammation followed by cancer.4 In the case of malignancy of the prostate, 
the production of interleukin-6 (IL-6) and other inﬂ  ammatory mediators may confer 
a survival advantage to local stem cells, which has been proposed as a method to 
facilitate tumorigenesis.4 Autocrine signaling loops may cause initiation of tumors, 
and perhaps cause dysfunction in the stem cells.4 Other reports have implicated auto-
immune conditions and infections in cancer development.1 Current knowledge on Journal of Inﬂ  ammation Research 2009:2 14
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inflammation-induced carcinogenesis is limited but the 
widespread implications of this phenomenon on human 
health warrant further studies.
The inﬂ  ammatory response can be triggered by pathologi-
cal conditions as such as hypoxia-ischemia. This pathological 
state in newborns has been shown to elicit a wide array of 
apoptotic responses.5 This information, when combined with 
the involvement of cytokines, could extrapolate to prospects 
on cell death and protection of tumors.5 During perinatal 
distress, resuscitation of hypoxic-ischemic conditions with 
100% oxygen can result in shuttling of the Bax channel to 
various subcellular locations, leading to activation IL-1β and 
the inﬂ  ammatory response.5 Calpain and Bax levels in the 
endoplasmic reticulum are also increased, further supporting 
a role for cytokines in the biology of programmed cell death, 
and when extrapolated, in cancer cells.5
Integrins function in cancer 
development
Among the key molecules involved in the inﬂ  ammatory 
response are the integrins.6 Integrins are members of the 
cell adhesion molecule family. This family of molecules 
mediates interactions between cells and the extracellular 
matrix to facilitate cell migration, adhesion, differentiation, 
proliferation, angiogenesis, survival, and inﬂ  ammation.7 The 
integrins have roles in signal transduction by cytokine recep-
tors, G-protein-coupled receptors (GPCRs), and receptor 
tyrosine kinases (RTKs).8 In the neutrophil response to acute 
inﬂ  ammation, inﬂ  ammatory mediators from primary granules 
include heparin-binding protein, which leads to macrophage 
activation through β2-integrin.6 In Gram-negative infection, 
β2-integrin may function as the lipopolysaccharide receptor.9 
However, it should be noted that roles of integrins are not 
limited to inﬂ  ammation. Since the integrins have been impli-
cated in cancer biology, it has been proposed that integrin 
blockers may synergize with chemotherapy and radiation for 
treatment of malignancies.7
The bridge between cancer and integrins is evident from 
the observation of anoikis, deﬁ  ned as apoptosis following loss 
of cell adhesion.10 Integrins are responsible for anchorage-
dependent cell survival, and, along with cadherins, they pre-
vent cancer development.11 Anoikis is vital for maintenance 
of tissue integrity because it prevents defective cells from 
replicating.12 Without the ability to adhere to surrounding 
surface, cells could travel and proliferate in inappropriate 
regions. A central property of cancer cells is the ability to 
avoid anchorage and to proliferate in the absence of integrin 
and cadherin expression.12
In untransformed cells, integrin-induced adhesion leads 
to cell cycle progression, speciﬁ  cally throughout the G1 
phase.7 Adhesion molecules also regulate entry into S phase, 
as integrins interact with cyclin E/cdk2.13 Integrins and cell 
signaling receptors cooperate to modulate cell cycle progres-
sion by regulating cyclin D1 expression at the transcriptional 
and post-translational levels.7 These ﬁ  ndings suggest that the 
mechanisms by which cell anchorage molecules regulate cell 
function should be explored in more detail considering the 
signiﬁ  cance in different pathological conditions, including 
tumorigenesis.
As the cancer stem cell hypothesis gains acceptance, 
it is important to understand how the molecules central 
to cancer development are involved in stem cell biology. 
Such an understanding might lead to the identiﬁ  cation of 
the elusive cancer stem cells. Embryonic stem cells lack-
ing β1-integrin fail to differentiate, substantiating a role 
for integrins in the differentiation of pluripotent cells.14 
Conversely, β1-integrin deﬁ  ciency in neuronal tissue facili-
tates cell differentiation.7 A speciﬁ  c oncogenic β1-integrin 
mutation appears to facilitate ligand binding and to hinder 
differentiation of skin cells.7 We can therefore speculate 
that these ligand-binding events can promote development 
of high-grade malignancies.
Pro-inﬂ  ammatory cytokines have 
diverse roles in cancer
The prospect of cytokine involvement in malignancy has 
received attention. This section discusses two cytokines: IL-2 
and IL-21 due to their similarities and sharing of the γ-chain 
subunit of the receptor.15 Despite this similarity, these two 
cytokines have opposing effects. IL-2, for example, promotes 
the maturation of cytotoxic T lymphocytes to granzyme 
B-expressing cells while IL-21 inhibits these processes.15 
IL-2 also promotes the development of regulatory T (Treg) 
cells and aids in the activation and expansion of T cells that 
can lyse tumor cells.15 These experimental ﬁ  ndings have led 
to the application of IL-2 in anti-cancer therapies.16 Inves-
tigators have suggested that the antagonistic relationship 
between IL-2 and IL-21 can be vital to the use of T cells 
for immunotherapy for cancer, and perhaps other immune-
mediated disorders.15
Another relevant inﬂ  ammatory cytokine is tumor necro-
sis factor-α (TNF-α), a macrophage pro-inflammatory 
cytokine that appears to have a bimodal effect on tumori-
genesis.17 Whereas it facilitates proliferation of tumor 
cells such as those of the lung, it also exerts pro-apoptotic 
effects.18 The oncogenic effects are evident in that TNF-α Journal of Inﬂ  ammation Research 2009:2 15
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facilitates proliferation of cells in breast cancer and renal cell 
carcinoma.17,19 These ﬁ  ndings may explain why TNF-α- and 
TNF-α-receptor-deﬁ  cient mice are less susceptible to carci-
nogenesis.17 On the other end of the spectrum, TNF-α therapy 
for treatment of cancer has been investigated. Although 
groups of low-invasive carcinoma cells have been identiﬁ  ed 
as TNF-α-sensitive, others have shown resistance.18 Inves-
tigations into the mechanisms of breast cancer resistance to 
TNF-α therapy are warranted if the future of cancer therapy 
includes this valuable cytokine. In any case, the speciﬁ  c 
delivery of TNF-α is critical in order for it to be successful 
in the clinic, as TNF-α is toxic to normal body functions.18
Chemokines
Chemokines are a family of small molecules that facilitate 
cell movement via adhesion and migration.20 They alter the 
functions of target cells by paracrine, endocrine, and auto-
crine stimulation.21 Chemokine receptors, such as CXCR4, 
in malignant cells have been shown to promote cell prolifera-
tion, migration, and maintenance. Such events contribute to 
metastasis, such as the role of one chemokine family, stromal 
cell-derived factor-1α (SDF-1α) in breast cancer invasion 
and metastasis to bone marrow.21,22
SDF-1α and its receptor CXCR4 are crucial to migra-
tion of breast cancer cells to sites of distant metastasis, 
such as bone marrow, lung, liver, and brain.22 Expression of 
SDF-1α in breast cancer cells assists in cellular and vascular 
proliferation.21 These ﬁ  ndings are consistent with studies 
demonstrating that plasma levels of SDF-1α are higher in 
patients with breast cancer than healthy individuals.22 On the 
contrary, this chemokine/receptor pair appears to promote 
quiescence of malignant breast cells in the marrow cavity.22 
In contrast to carcinoma, normal breast tissue expresses low 
levels of CXCR4, substantiating the cancer-inducing nature 
of the SDF-1α/CXCR4 axis. In addition to SDF-1α, another 
member of the chemokine family, monocyte chemotactic 
protein-1 (MCP-1), is particularly important to breast cancer.23 
MCP-1 is secreted by various immune cell types and plays an 
integral role in advanced breast cancer progression.23 It func-
tions in molecular interactions with the microenvironment.23 
MCP-1 also recruits immune cells, such as macrophages, to 
sites of inﬂ  ammation.21 The link to cancer is evident in studies 
demonstrating high levels of MCP-1 secretion by tumor cells. 
In patients with acute lymphoblastic leukemia, for example, 
MCP-1 levels are signiﬁ  cantly elevated during treatment, 
suggesting a regulatory mechanism in this cancer.24
Inﬂ  ammation in the brain is partly regulated by the SDF-
1α/CXCR4 axis, the same interaction that governs breast 
cancer metastasis to the bone marrow.25 Normally, SDF-1α 
is expressed by bone marrow stromal cells, and CXCR4 is 
expressed on the surface of breast cancer cells.22 The inter-
action between these two molecules has been suggested to 
facilitate dormancy of breast cancer in the bone marrow. 
SDF-1α knockdown in breast cancer cells leads to reduced 
efﬁ  ciency of cancer cell entry into bone marrow.22 Clearly, 
inﬂ  ammation plays an essential role in various types of stem 
cell events.
It is clear that the role of chemokines in breast cancer 
is great and the potential for chemokine-targeted treatment 
is very appealing. Interestingly, evidence suggests that the 
expression of the chemokines SDF-1α and MCP-1 can 
be regulated by endogenous hormones.21 The prospect of 
regulation by endogenous hormones suggests a role for 
supplemental hormones as well. Therefore, the hormonal 
suppression of these metastasis-promoting chemokines may 
be one potential breast cancer treatment method.
NFκB transcription factor 
in inﬂ  ammation and tumorigenesis
The transcription factor NFκB has been of interest for inﬂ  am-
matory-mediated responses, mostly because several cyto-
kines cause the activation of this transcription factor.26 The 
major subunits of activated NFκB are p50 and p65. NFκB 
is activated when the inhibitor kappaB (IκB) is phosphory-
lated by IκB kinase (IKK).26 Its phosphorylation permits 
translocation to the nucleus and transcriptional activation 
of several genes.26 The functions of NFκB span diverse cel-
lular processes, including adhesion, proliferation, apoptosis, 
differentiation, immune regulation, and angiogenesis.27 The 
most common conditions associated with NFκB signaling 
are chronic inflammatory diseases, such as rheumatoid 
arthritis, psoriatic arthritis, celiac disease, ulcerative colitis, 
and Crohn’s disease.27
The NFκB pathway may be central to the process of 
atherosclerosis with regards to inﬂ  ammation of the vascular 
endothelium.28 Lymphotoxin family members, including 
TNF-α, appear to employ NFκB signaling in vessel injury.28 
Lymphotoxin-α, for example, increases VCAM1 expression 
on endothelial cells in an NFκB-dependent manner.28 These 
ﬁ  ndings are consistent with demonstrations of the rescue of 
NFκB effector function by TNF-α.26 The precise mechanism 
of TNF-α-mediated activation of NFκB signaling may be 
through the inhibition of IκB.29
The role of NFκB in pulmonary edema has recently 
been investigated. NFκB expression increased 13-fold dur-
ing periods of hypoxia in patients with pulmonary edema.30 Journal of Inﬂ  ammation Research 2009:2 16
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The DNA-binding function of NFκB was also increased, 
suggesting that NFκB activity may be a response to oxidative 
stress produced by free radical generation under hypoxic con-
ditions.30 In addition to NFκB upregulation, levels of other 
pro-inﬂ  ammatory cytokines such as TNF-α and acute phase 
reactants such as IL-1 and IL-6 increased.30 Treatment with 
curcumin, an NFκB antagonist, prevented the inﬂ  ammatory 
response associated with hypoxia, speciﬁ  cally vascular leak-
age in the lungs.30 The role of NFκB in pulmonary tissue is 
not completely understood at this point, yet it appears to be 
vital in hypoxia-induced stress.
The implications of NFκB in hypoxia are not limited 
to pulmonary edema, but encompass other pathological 
processes. NFκB may mediate the response to ischemic 
pre-conditioning and cardioprotection of the heart.31 The 
activation of the NFκB pathway followed by KATP channel 
opening mediates cardio- and renal-protective events.31
In addition to its role in these processes, NFκB may 
be an important mediator in the disease processes of type 
II diabetes mellitus and the metabolic syndrome.32 Reac-
tive oxygen species and reactive nitrogen species activate 
NFκB and subsequent transcription of TNF-α. This series 
of events has been linked to insulin resistance in skeletal 
muscle, thereby suggesting a role for NFκB in diabetes and 
metabolic syndrome.32
Although much attention regarding NFκB has focused on 
inﬂ  ammatory states, the current upsurge of interest in stem 
cell biology has led to studies of the function of NFκB in 
stem cells of the bone marrow. NFκB has been suggested to 
regulate secretion of growth factors and cytokines in adult 
and neonatal stem cells from the bone marrow environment.22 
Vascular endothelial growth factor (VEGF) was decreased 
upon IKK inhibition in adult stem cells.26 This effect was 
completely reversed by TNF-α, a member of the lymphotoxin 
family.26,28 Furthermore, IL-6 levels were decreased upon 
NFκB inhibition in both adult and neonatal stem cells.26 
These ﬁ  ndings suggest that NFκB is pivotal in production 
of VEGF by stem cells. Aside from bone marrow stem cells, 
neural stem cells also employ the NFκB pathway, which 
facilitates migration, proliferation, and differentiation of 
these stem cells.33 Although these ﬁ  ndings have demonstrated 
a role of NFκB in stem cell biology, our knowledge in this 
area is still incomplete and therefore under investigation by 
our laboratory.
Recent literature has pointed to the role of NFκB in 
malignant processes, as numerous cancers demonstrate 
dysregulation of the NFκB pathway.34 The metastatic oral 
squamous cell carcinoma line HSC3, for example, showed 
signiﬁ  cantly higher levels of the p65 subunit of NFκB.34 
Furthermore, TNF-α signaling depends on NFkB in the 
malignant keratinocytes of squamous cell carcinoma of the 
skin.35 In gastric carcinoma, NFκB exerts an anti-apoptotic 
effect via upregulation of the survivin gene.36
A multitude of other pathological processes involve 
NFκB but have not been thoroughly investigated thus far. 
For example, an anti-apoptotic function of NFκB has been 
suggested for osteoclasts. Transforming growth factor-β 
(TGF-β) utilizes the NFκB pathway, in addition to other 
pathways, to prevent programmed cell death of osteoclasts. 
Multiple pathways, including the TAK1/MEK pathway, are 
involved in the NFκB-mediated anti-apoptotic effect.37 NFκB 
appears to play a role in regulation of spermatogenesis.38 It 
appears to regulate the junctional complexes between Sertoli 
cells and spermatids.39 Clearly, the implications of NFkB are 
vast, and future studies on this master regulator hold great 
potential in treatment of disease processes.
Stem cells and inﬂ  ammation
The processes underlying tissue injury and repair following 
inﬂ  ammation have been studied, and the evidence suggests 
stem cell involvement.40 The induction of an inﬂ  ammatory 
response by IL-1 in the lacrimal gland has provided insights 
into mechanisms of inﬂ  ammation on stem cells.40 In this 
study, acinar cells of the lacrimal gland underwent apoptosis 
and autophagy.40 Interestingly, the acinar cells expressed 
the stem cell marker nestin and the cell proliferation marker 
Ki67.40 These studies suggest that lacrimal cells may revert 
to a stem-like phenotype upon induction of inﬂ  ammation, or 
they may contain stem cells that function to regenerate the 
parenchyma of the organ.
The effects of inﬂ  ammation on neural stem cell activity 
is interesting and currently under investigation. Inﬂ  amma-
tion of the brain has been suggested to lead to neurological 
diseases including Parkinson’s disease, Alzheimer disease, 
and depression.41 Throughout the process of inﬂ  ammation, 
the generation of neuronal cells of the adult brain is affected, 
suggesting that neuroinﬂ  ammation may offer therapeutic 
potential for neurodegenerative diseases.41
Neural progenitors and stem cells have been postulated 
to promote neuroprotection via regulation of the immune 
response.42 Stem cells can interact with the host immune 
system to facilitate host recovery.41 The reciprocal protective 
relationship between stem cells and inﬂ  ammatory responses 
is evident from the hypothesis that IL-6 and other inﬂ  am-
matory mediators can facilitate survival of stem cells of 
the prostate epithelium in patients with prostate cancer.4,43 Journal of Inﬂ  ammation Research 2009:2 17
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The process of inﬂ  ammation can adversely affect neural 
stem cell grafts because neural progenitors and stem cells 
express cell surface receptors for products of the inﬂ  amma-
tory response.41 Thus, the precise time at which stem cell 
transplants are administered may be important in bypassing 
inﬂ  ammation.41
Mesenchymal stem cell therapy
for inﬂ  ammatory-mediated disorders
Mesenchymal stem cells (MSCs) offer considerable therapeutic 
value in modulating inﬂ  ammation and graft rejection.44 It is 
their anti-inﬂ  ammatory properties rather than their potential 
as stem cells that warrant their ﬁ  rst clinical application.45 
One of the most serious concerns regarding bone marrow 
transplantation is graft-versus-host-disease (GVHD), which 
is a pathology characterized by an immune response of the 
maturing donor lymphocytes against antigens of the recipi-
ent.45 GVHD induces systemic inﬂ  ammation and often results 
in death of the recipient.45 The immune properties of MSCs 
confer them with pharmacological potential in the regulation 
of conditions such as GVHD and other inﬂ  ammatory pro-
cesses.46 In addition to GVHD, MSC therapy has implications 
in Charcot–Marie–Tooth disease, an inherited neuropathy 
characterized by demyelination of peripheral nerves.45
As for the bimodal property of MSC behavior, it appears 
that the level of expression is key. An abundance of MSCs 
leads to immunosuppressive behavior, whereas sparse MSC 
presence induces immunostimulation.47 MSCs have the ability 
to suppress immune reactions via activating Treg cells and pre-
venting the maturation of functional dendritic cells.48,49 This 
is of particular relevance to hematopoietic stem cell (HSC) 
transplants because T-cell–derived inﬂ  ammatory cytokines 
such TNF-α and IFN-γ suppress hematopoiesis.45 Therefore, 
MSCs transplanted along with HSCs can guard them from 
destruction by inﬂ  ammatory cytokines. Furthermore, research 
has shown that MSCs are capable of producing immune sup-
pressive factors such as HLA-G, prostaglandin E2, IL-10, 
and TGF-β, which strengthens their anti-inflammatory 
properties.45 Currently, phase III clinical trials are in progress 
for the use of MSCs in suppressing inﬂ  ammatory immune 
responses associated with GVHD, Crohn’s disease, and 
Charcot–Marie–Tooth syndrome.45
Obstacles to stem cell therapy
We have described numerous beneﬁ  ts of stem cell therapy thus 
far. Intravenous MSC treatments have already been shown to 
decrease expression of numerous pro-inﬂ  ammatory cytokines 
such as IFN-γ and TNF-α.29 Due to the correlation between 
the inﬂ  ammatory process and carcinogenesis, tumorigenesis, 
angiogenesis, and metastasis, it is clear that the inhibition of 
the autoimmune response could be a successful anti-cancer 
measure. While the utilization of their immunosuppressive 
properties is a promising theory, MSCs present two major 
obstacles: their oncogenic properties and their senescence-
induced degradation.51 MSCs have been shown to stimulate 
the immune response in some instances, which, due to the 
connection between inﬂ  ammation and carcinogenesis, is a 
serious concern. As for senescence, while it is still a lively 
debate amongst scientists, there are many who have found 
evidence that shows that the capabilities and effectiveness of 
MSCs decrease as they age.51 While oncogenesis is the greater 
concern, both of these complications must be resolved before 
MSC treatment for cancer is widespread.
Conclusions
As discussed here, the outlook on cancer biology and stem 
cell therapy is not complete without considering inﬂ  amma-
tory events. Cytokines could be important in the battle against 
malignancies of the breast and other tissues, either directly or 
by studying their roles and identifying targets. IL-2-mediated 
tumor cell lysis implies the signiﬁ  cance of cell-based therapy 
in carcinogenesis. Integrin antagonists are another interesting 
tool as they regulate differentiation, survival, and angiogenesis, 
thereby making their presence essential in the prevention of 
cancer. While a treatment of integrin antagonists alone may 
not be in the immediate future, evidence shows that they may 
greatly enhance the effects of chemotherapy and radiotherapy. 
As with any proposed treatment, however, integrin antagonist 
treatment has a major difﬁ  culty. Targeting the speciﬁ  c integ-
rins of breast cancer cells would prove to be an extraordinarily 
difﬁ  cult task, and before such speciﬁ  city can be guaranteed, 
this treatment may be dangerous to the patient. Overall, the role 
of MSCs may extend to conditions with signiﬁ  cant inﬂ  amma-
tory and autoimmune components. In any case, science must 
be aware of the obstacles to stem cell therapy before these 
cells can be administered in a clinical setting.
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